OMEROS CORP. news, videos and press releases
For more news please use our advanced search feature.
OMEROS CORP. - More news...
OMEROS CORP. - More news...
- Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
- Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
- Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
- Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
- Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
- Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
- Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
- Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
- Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
- Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
- Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
- Omeros Corporation Provides Update on Progress Toward BLA Resubmission
- Omeros Corporation Reports Third Quarter 2024 Financial Results
- Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
- Omeros Corporation Reports Second Quarter 2023 Financial Results
- Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
- Omeros Announces Webcast Details for Annual Meeting of Shareholders
- Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
- Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
- Omeros Corporation Reports First Quarter 2023 Financial Results
- Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
- Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
- Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
- Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
- Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
- Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
- Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
- Omeros Corporation Reports Third Quarter 2022 Financial Results
- Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
- Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
